25
Feb
2010
05
May
2009
Posted in I - Series A, Q - 2Q09, R - MID WEST, X - IBD, X - Lupus, X - RA, X - Therapeutic Platform, XX - MI
Lycera Corp (Ann Arbor, MA) a preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease, closed a $36M Series A financing. Participants include InterWest Partners, ARCH Venture Partners, Clarus Ventures and EDF Ventures.
02
Apr
2007
Posted in I - Series D, R - WEST, X - IBD, X - Inflammation, X - Oncology
ChemoCentryx (Mountain View, CA) a developer of drugs for autoimmune diseases, inflammatory diseases and oncology with lead indications for inflammatory bowel disease and multiple sclerosis, closed a $29.9M Series D finanicing. The deal was led by the Glaxo Group Ltd. and was joined by Alta Partners, GIMV, HBM BioVentures and OrbiMed Advisors.